• Je něco špatně v tomto záznamu ?

Inhibition of Lipolysis Ameliorates Diabetic Phenotype in a Mouse Model of Obstructive Sleep Apnea

M. Weiszenstein, LA. Shimoda, M. Koc, O. Seda, J. Polak,

. 2016 ; 55 (2) : 299-307.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031827
E-zdroje Online Plný text

NLK Free Medical Journals od 1997-07-01 do Před 1 rokem
ProQuest Central od 1994-01-01 do Před 9 měsíci
ProQuest Central od 2011-01-01 do 2019-09-30
Health & Medicine (ProQuest) od 2011-01-01 do 2019-09-30

Obstructive sleep apnea (OSA) is associated with insulin resistance, glucose intolerance, and type 2 diabetes. Causal mechanisms mediating this association are not well defined; however, augmented lipolysis in adipose might be involved. Here, we investigated the effect of acipimox treatment (lipolysis inhibitor) on glucose tolerance and insulin sensitivity in mice exposed to intermittent hypoxia (IH). C57BL6/J mice were exposed for 14 days to IH or control conditions. IH was created by decreasing the fraction of inspired oxygen from 20.9 to 6.5%, 60 times/h. Control exposure was air (fraction of inspired oxygen, 20.9%) delivered at an identical flow rate. Acipimox was provided in drinking water (0.5 g/ml) during exposures. After exposures, intraperitoneal insulin (0.5 IU/kg) and glucose (1 g/kg) tolerance tests were performed, and primary adipocytes were isolated for lipolysis experiments. IH elevated fasting glucose by 51% and worsened glucose tolerance and insulin sensitivity by 33 and 102%, respectively. In parallel, IH increased spontaneous lipolysis by 264%, and reduced epididymal fat mass by 15% and adipocyte size by 8%. Acipimox treatment prevented IH-induced lipolysis and increased epididymal fat mass and adipocyte size by 19 and 10%, respectively. Acipimox fully prevented IH-induced impairments in fasting glycemia, glucose tolerance, and insulin sensitivity. For all reported results, P less than 0.05 was considered significant. Augmented lipolysis contributes to insulin resistance and glucose intolerance observed in mice exposed to IH. Acipimox treatment ameliorated the metabolic consequences of IH and might represent a novel treatment option for patients with obstructive sleep apnea.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031827
003      
CZ-PrNML
005      
20171030102214.0
007      
ta
008      
171025s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1165/rcmb.2015-0315OC $2 doi
035    __
$a (PubMed)26978122
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Weiszenstein, Martin $u 1 Center for Research on Diabetes, Metabolism, and Nutrition, Third Faculty of Medicine. 2 Center of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic.
245    10
$a Inhibition of Lipolysis Ameliorates Diabetic Phenotype in a Mouse Model of Obstructive Sleep Apnea / $c M. Weiszenstein, LA. Shimoda, M. Koc, O. Seda, J. Polak,
520    9_
$a Obstructive sleep apnea (OSA) is associated with insulin resistance, glucose intolerance, and type 2 diabetes. Causal mechanisms mediating this association are not well defined; however, augmented lipolysis in adipose might be involved. Here, we investigated the effect of acipimox treatment (lipolysis inhibitor) on glucose tolerance and insulin sensitivity in mice exposed to intermittent hypoxia (IH). C57BL6/J mice were exposed for 14 days to IH or control conditions. IH was created by decreasing the fraction of inspired oxygen from 20.9 to 6.5%, 60 times/h. Control exposure was air (fraction of inspired oxygen, 20.9%) delivered at an identical flow rate. Acipimox was provided in drinking water (0.5 g/ml) during exposures. After exposures, intraperitoneal insulin (0.5 IU/kg) and glucose (1 g/kg) tolerance tests were performed, and primary adipocytes were isolated for lipolysis experiments. IH elevated fasting glucose by 51% and worsened glucose tolerance and insulin sensitivity by 33 and 102%, respectively. In parallel, IH increased spontaneous lipolysis by 264%, and reduced epididymal fat mass by 15% and adipocyte size by 8%. Acipimox treatment prevented IH-induced lipolysis and increased epididymal fat mass and adipocyte size by 19 and 10%, respectively. Acipimox fully prevented IH-induced impairments in fasting glycemia, glucose tolerance, and insulin sensitivity. For all reported results, P less than 0.05 was considered significant. Augmented lipolysis contributes to insulin resistance and glucose intolerance observed in mice exposed to IH. Acipimox treatment ameliorated the metabolic consequences of IH and might represent a novel treatment option for patients with obstructive sleep apnea.
650    _2
$a tukové buňky $x účinky léků $x patologie $7 D017667
650    _2
$a adipozita $x účinky léků $7 D050154
650    _2
$a zvířata $7 D000818
650    _2
$a experimentální diabetes mellitus $x krev $x komplikace $x genetika $x patologie $7 D003921
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a mastné kyseliny $x krev $7 D005227
650    _2
$a regulace genové exprese $x účinky léků $7 D005786
650    _2
$a glukosa $x metabolismus $7 D005947
650    _2
$a hypoxie $x komplikace $x metabolismus $7 D000860
650    _2
$a inzulin $x metabolismus $7 D007328
650    12
$a lipolýza $x účinky léků $7 D008066
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a fenotyp $7 D010641
650    _2
$a pyraziny $x farmakologie $7 D011719
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a obstrukční spánková apnoe $x krev $x komplikace $x genetika $x patologie $7 D020181
655    _2
$a časopisecké články $7 D016428
700    1_
$a Shimoda, Larissa A $u 3 Division of Pulmonary and Critical Care Medicine, Asthma and Allergy Center, Johns Hopkins School of Medicine, Baltimore, Maryland.
700    1_
$a Koc, Michal $u 4 Sports Medicine Department, Third Faculty of Medicine, and.
700    1_
$a Seda, Ondrej $u 5 Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; and.
700    1_
$a Polak, Jan $u 1 Center for Research on Diabetes, Metabolism, and Nutrition, Third Faculty of Medicine. 2 Center of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic. 3 Division of Pulmonary and Critical Care Medicine, Asthma and Allergy Center, Johns Hopkins School of Medicine, Baltimore, Maryland. 6 Second Internal Medicine Department, Vinohrady Teaching Hospital, Prague, Czech Republic.
773    0_
$w MED00000298 $t American journal of respiratory cell and molecular biology $x 1535-4989 $g Roč. 55, č. 2 (2016), s. 299-307
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26978122 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171030102303 $b ABA008
999    __
$a ok $b bmc $g 1255420 $s 992854
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 55 $c 2 $d 299-307 $i 1535-4989 $m American journal of respiratory cell and molecular biology $n Am J Respir Cell Mol Biol $x MED00000298
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...